



## **Syndax Pharmaceuticals to Present at Bio CEO & Investor Conference**

Waltham, Mass. – Feb. 10, 2011 – Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the 13th Annual Bio CEO and Investor Conference on Monday, February 14, 2011 at 8:00 a.m. ET at the Waldorf-Astoria in New York city. Dr. Horobin's presentation will include the recently reported results from a randomized phase 2 study, which showed a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. In addition, she will review the ongoing phase 2 clinical programs for entinostat in breast, lung, colorectal cancer and hematologic malignancies.

### **About Syndax**

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit [www.syndax.com](http://www.syndax.com).

### **Contact Information**

E. Blair Schoeb  
Syndax Pharmaceuticals, Inc  
Tel: 908-277-0386  
[bschoeb@syndax.com](mailto:bschoeb@syndax.com)